Alpha Cognition (NASDAQ:ACOG) COO Buys $20,160.00 in Stock

Alpha Cognition Inc. (NASDAQ:ACOG) COO Lauren D’angelo purchased 3,500 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $5.76 per share, for a total transaction of $20,160.00. Following the completion of the transaction, the chief operating officer directly owned 140,695 shares of the company’s stock, valued at approximately $810,403.20. This represents a 2.55% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Alpha Cognition Price Performance

NASDAQ ACOG traded up $0.05 on Tuesday, hitting $5.80. 15,646 shares of the stock were exchanged, compared to its average volume of 61,865. The business’s fifty day moving average is $6.07 and its 200 day moving average is $5.91. Alpha Cognition Inc. has a 52 week low of $4.50 and a 52 week high of $11.54. The company has a market capitalization of $126.29 million, a PE ratio of -4.30 and a beta of 2.38.

Alpha Cognition (NASDAQ:ACOG) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.04. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%. The firm had revenue of $3.53 million for the quarter, compared to analyst estimates of $3.42 million. Analysts predict that Alpha Cognition Inc. will post -1.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Alpha Cognition in a report on Monday, April 27th. Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Finally, Craig Hallum assumed coverage on shares of Alpha Cognition in a report on Friday, April 17th. They set a “buy” rating and a $14.00 target price for the company. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Alpha Cognition presently has a consensus rating of “Buy” and an average price target of $16.00.

Hedge Funds Weigh In On Alpha Cognition

A number of large investors have recently made changes to their positions in the company. Aristides Capital LLC increased its stake in shares of Alpha Cognition by 1.4% during the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after purchasing an additional 3,052 shares during the period. Ikarian Capital LLC boosted its position in shares of Alpha Cognition by 11.6% in the fourth quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock valued at $6,866,000 after acquiring an additional 110,000 shares during the period. Sphera Funds Management LTD. boosted its position in shares of Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock valued at $3,690,000 after acquiring an additional 228,864 shares during the period. Opaleye Management Inc. boosted its position in shares of Alpha Cognition by 1,698.5% in the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock valued at $13,460,000 after acquiring an additional 1,955,642 shares during the period. Finally, ACT Capital Management LLC bought a new stake in shares of Alpha Cognition in the fourth quarter valued at about $335,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.